Dr. Jonasch on next steps with belzutifan in renal cell carcinoma

Eric Jonasch, MD, discusses the next research steps with the HIF-2α inhibitor belzutifan in patients with renal cell carcinoma. At the 2022 ASCO Annual Meeting, Jonasch shared findings from the abstract, “Phase 1 LITESPARK-001 (MK-6482-001) study of the HIF-2α inhibitor belzutifan in advanced solid tumors: Update of the clear cell renal cell carcinoma (ccRCC) cohort with more than 3 years of total follow-up.”

In the video, Jonasch says based on the efficacy in LITESPARK-001, the phase 3 LITESPARK-005 study has already been launched. Jonasch is a professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.